CPIP Bids a Fond Farewell to Kevin Madigan and Seeks New Deputy Director

Longtime CPIP staff member Kevin Madigan is leaving the Center next week to become VP, Legal Policy and Copyright Counsel at the Copyright Alliance. “I joined CPIP just over four years ago, and my time with the Center and Scalia Law has been rewarding on so many levels. The knowledge I’ve gained and the relationships … Continue reading “CPIP Bids a Fond Farewell to Kevin Madigan and Seeks New Deputy Director”

A Message From CPIP on Giving Tuesday

As we enter the holiday season and look ahead to 2020, we hope that you will keep CPIP in mind as you plan your end-of-year giving. Your support is critical to ensuring that CPIP continues its activities and works to engage academics, creators, and innovators in a scholarly dialogue on the importance of intellectual property. … Continue reading “A Message From CPIP on Giving Tuesday”

CPIP Roundup – November 29, 2019

Greetings from CPIP Executive Director Sean O’Connor As we wind down the Thanksgiving holiday here in the U.S., the CPIP team is grateful for many things, most especially your support. If you are spending time with family—or enjoying a “Friendsgiving”—we hope it has been restful. As part of CPIP’s enhanced focus on international engagement, I … Continue reading “CPIP Roundup – November 29, 2019”

CPIP Roundup – October 31, 2019

Greetings from CPIP Executive Director Sean O’Connor CPIP started a busy and productive October with our Seventh Annual Fall Conference, The IP Bridge: Connecting the Lab & Studio to the Market, which featured—among many informative and well-received panels and presentations—keynote addresses by Professor Robert Merges of UC Berkeley and Maria Pallante of AAP. The video … Continue reading “CPIP Roundup – October 31, 2019”

The CASE Act: Why Creators Need a Small Claims Tribunal

The Center for the Protection of Intellectual Property (CPIP) and the Intellectual Property Law Society (IPLS) at Antonin Scalia Law School, George Mason University, invite you to a panel discussion on the CASE Act. The CASE Act: Why Creators Need a Small Claims Tribunal Thursday November 14, 2019 4:45 – 6:00 PM Antonin Scalia Law … Continue reading “The CASE Act: Why Creators Need a Small Claims Tribunal”

CPIP Roundup – September 30, 2019

Greetings from CPIP Executive Director Sean O’Connor The fall semester is now in full swing at Antonin Scalia Law School, and the CPIP team has been busy this past month with our various programs and events. On September 12-13, we hosted the third meeting of the 2019-2020 Thomas Edison Innovation Fellowship, where the Edison Fellows … Continue reading “CPIP Roundup – September 30, 2019”

George Mason University’s Antonin Scalia Law School Launches Innovation Law Clinic

Scalia Law Will Serve Emerging Tech Sector in the DMV George Mason University’s Antonin Scalia Law School today announced the launch of its new Innovation Law Clinic to support the emerging, dynamic tech sector in the DMV (DC, MD, No VA). Sean O’Connor, a distinguished innovation scholar and Executive Director of Scalia Law’s Center for … Continue reading “George Mason University’s Antonin Scalia Law School Launches Innovation Law Clinic”

CPIP Roundup – August 29, 2019

Greetings from CPIP Executive Director Sean O’Connor With a new academic year beginning at Antonin Scalia Law School, the CPIP team continues to build on a productive summer of scholarship, events, and more. Our WIPO-CPIP Summer School on Intellectual Property this past June boasted 70 students from 30 countries for a two-week crash course on … Continue reading “CPIP Roundup – August 29, 2019”

New York Times Recycles Discredited Positions on Government Patent Rights over Pharmaceuticals

By Sean O’Connor The New York Times is at it again. A year after its Editorial Board promoted flawed research on government rights to patented drugs as part of a price control plan, the Board floated the idea again, together with misinformation about the Bayh-Dole Act. Advocates looking for a magic bullet to reduce drug … Continue reading “New York Times Recycles Discredited Positions on Government Patent Rights over Pharmaceuticals”

“No Combination Drug Patents Act” Stalls, but Threats to Innovation Remain

By Kevin Madigan & Sean O’Connor This week, the Senate Judiciary Committee was to mark up a bill limiting patent eligibility for combination drug patents—new forms, uses, and administrations of FDA approved medicines. While the impetus was to curb so-called “evergreening” of drug patents, the effect would have been to stifle life-saving therapeutic innovations. Though … Continue reading ““No Combination Drug Patents Act” Stalls, but Threats to Innovation Remain”